Promising new agents for treatment of patients with colorectal cancer.
Colorectal cancer continues to be a major problem. There are a number of new agents with promising clinical activity, including the multitargeted antifolate LY 231514 and the thymidylate synthesis inhibitor capecitabine. In addition, other agents have shown promising preclinical activity against the disease: 6-hydroxymethylacylfulvene (HMAF; MGI 114), LY 295501, bizelesin (U-7779; NSC615291), and ONYX-015. Finally, several agents may prevent colorectal cancer through prevention of the formation of colorectal polyps (eg, cyclooxygenase inhibitors).
Von Hoff
D D
DD
Institute for Drug Development, Department of Medicine, The University of Texas Health Science Center at San Antonio, 78245, USA.
D000256:Adenoviridae / Q000235:genetics; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001572:Benzofurans / Q000627:therapeutic use; D015179:Colorectal Neoplasms / Q000188:drug therapy*; D004354:Drug Screening Assays, Antitumor; D000080890:Duocarmycins; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D006801:Humans; D007211:Indoles / Q000627:therapeutic use; D010671:Phenylurea Compounds / Q000627:therapeutic use; D012717:Sesquiterpenes / Q000627:therapeutic use; D013940:Thymidylate Synthase / Q000037:antagonists & inhibitors; D014407:Tumor Cells, Cultured; D014508:Urea / Q000031:analogs & derivatives / Q000627:therapeutic use
D000970:Antineoplastic Agents; D001572:Benzofurans; D000080890:Duocarmycins; D004791:Enzyme Inhibitors; D007211:Indoles; D010671:Phenylurea Compounds; D012717:Sesquiterpenes; C094382:N-(5-(2,3-dihydrobenzofuryl)sulfonyl)-N'-(3,4-dichlorophenyl)urea; C102714:irofulven; D014508:Urea; D013940:Thymidylate Synthase; C072257:bizelesin